Corpus overview


Overview

MeSH Disease

Transmission

Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 1 records in total 1
    records per page




    Association between autoimmune diseases MESHD and COVID-19 MESHD as assessed in both a test-negative case-control and population case-control design

    Authors: Rossella Murtas; Anita Andreano; Federico Gervasi; Davide Guido; David Consolazio; Sara Tunesi; Laura Andreoni; Maria Teresa Greco; Maria Elena Gattoni; Monica Sandrini; Antonio Riussi; Antonio Giampiero Russo

    doi:10.21203/rs.3.rs-58948/v1 Date: 2020-08-13 Source: ResearchSquare

    Background: COVID-19 MESHD epidemic has paralleled with the so called infodemic, where countless pieces of information have been disseminated on putative risk factors for COVID-19 MESHD. Among those, emerged the notion that people suffering from autoimmune diseases MESHD ( AIDs MESHD) have a higher risk of SARS-CoV-2 infection MESHD. Methods: The cohort included all COVID-19 MESHD cases residents in the Agency for Health Protection (AHP) of Milan that, from the beginning of the outbreak, developed a web-based platform that traced TRANS positive and negative cases as well as related contacts. AIDs MESHD subjects were defined ad having one the following autoimmune disease MESHD: rheumatoid arthritis HP rheumatoid arthritis MESHD, systemic lupus erythematosus MESHD systemic lupus erythematosus HP, systemic sclerosis MESHD, Sjogren disease, ankylosing spondylitis MESHD, myasthenia gravis MESHD, Hashimoto's disease MESHD, acquired autoimmune hemolytic anemia HP autoimmune hemolytic anemia MESHD, and psoriatic arthritis MESHD arthritis HP. To investigate whether AID subjects are at increased risk of SARS-CoV-2 infection MESHD, and whether they have worse prognosis than AIDs MESHD-free subjects once infected, we performed a combined analysis of a test-negative design case-control study, a case-control with test-positive as cases, and one with test-negative as cases (CC-NEG). Results: During the outbreak, the Milan AHP endured, up to April 27th 2020, 20,364 test-positive and 34,697 test-negative subjects. We found no association between AIDs MESHD and being positive to COVID-19 MESHD, but a statistically significant association between AIDs MESHD and being negative to COVID-19 MESHD in the CC-NEG. If, as likely, test-negative subjects underwent testing because of respiratory infection MESHD symptoms, these results imply that autoimmune diseases MESHD may be a risk factor for respiratory infections MESHD in general (including COVID-19 MESHD), but they are not a specific risk factor for COVID-19 MESHD. Furthermore, when infected by SARS-CoV-2, AIDs MESHD subjects did not have a worse prognosis compared to non- AIDs MESHD subjects. Results highlighted a potential unbalance in the testing campaign, which may be correlated to the characteristics of the tested person, leading specific frail population to be particularly tested.Conclusions: Lack of availability of sound scientific knowledge inevitably lead unreliable news to spread over the population, preventing people to disentangle them form reliable information. Even if additional studies are needed to replicate and strengthen our results, these findings represent initial evidence to derive recommendations based on actual data for subjects with autoimmune diseases MESHD.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.